An overview on different classes of viral entry and respiratory syncitial virus (RSV) fusion inhibitors.
The therapeutic approach to AIDS is based on the combination of different drugs in the highly active antiretroviral therapy (HAART) regimen. These drugs have a wide variety of side effects, and some strains of HIV can develop resistance: for these reasons new anti-HIV drugs are needed. In the wide field of anti-HIV medicine this review covers different classes of drugs which inhibit viral entry: in particular the classification of main categories, their mode of action and some new candidates for AIDS therapy are contemplated. Also covered in this review are respiratory syncytial virus (RSV) fusion inhibitors.
Murineddu
G
G
Dipartimento Farmaco Chimico Tossicologico, Facoltà di Farmacia, via F. Muroni 23/A, 07100 Sassari, Italy. muri@uniss.it
Murruzzu
C
C
Pinna
G A
GA
D019380:Anti-HIV Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000737:chemistry* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000737:chemistry / Q000627:therapeutic use; D023581:HIV Fusion Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D000069455:Palivizumab; D010455:Peptides / Q000737:chemistry / Q000627:therapeutic use; D010636:Phenols / Q000737:chemistry / Q000627:therapeutic use; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*; D013449:Sulfonamides / Q000737:chemistry / Q000627:therapeutic use
D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D001562:Benzimidazoles; D023581:HIV Fusion Inhibitors; D010455:Peptides; D010636:Phenols; D013449:Sulfonamides; D000069455:Palivizumab; C031000:benzimidazole